- Previous Close
1,086.30 - Open
1,074.00 - Bid 1,051.00 x --
- Ask 1,054.70 x --
- Day's Range
953.05 - 1,074.00 - 52 Week Range
597.00 - 1,359.00 - Volume
3,704 - Avg. Volume
13,179 - Market Cap (intraday)
268.044B - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
95.98 - EPS (TTM)
10.97 - Earnings Date May 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 9, 2022
- 1y Target Est
1,406.00
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
suvenpharm.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SUVENPHAR.BO
View MorePerformance Overview: SUVENPHAR.BO
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUVENPHAR.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUVENPHAR.BO
View MoreValuation Measures
Market Cap
276.53B
Enterprise Value
270.20B
Trailing P/E
99.39
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
26.87
Price/Book (mrq)
13.98
Enterprise Value/Revenue
26.16
Enterprise Value/EBITDA
61.42
Financial Highlights
Profitability and Income Statement
Profit Margin
26.63%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
10.48B
Net Income Avi to Common (ttm)
2.79B
Diluted EPS (ttm)
10.97
Balance Sheet and Cash Flow
Total Cash (mrq)
6.56B
Total Debt/Equity (mrq)
1.95%
Levered Free Cash Flow (ttm)
--